It is shown that proteins carried by circulating extracellular vesicles (EVs) can reflect and influence the efficacy of CLDN18.2-targeted therapies.
Abstract
Claudin 18.2 (CLDN18.2)-targeted CAR-T cell and antibody therapies show promise against gastrointestinal cancers, but biomarkers predictive of long-term benefit and therapeutic sensitization strategies are needed. Here we show that proteins carried by circulating extracellular vesicles (EVs) can reflect and influence the efficacy of CLDN18.2-targeted therapies. By profiling serial plasma samples of patients from the CT041-CG4006 trial (CLDN18.2- CAR-T-therapy) or the GLOW trial (Zolbetuximab), we identified EV-associated CLDN18.2, PD1 and PD-L2 as therapeutic markers and integrated them into a signature (CPP-score) for better predictive robustness. Mechanistically, specific EV-proteins exhaust CAR-T cells, neutralize CLDN18.2-targeted-antibodies, activate immunosuppressive IL-6-expressing cancer-associated fibroblasts, and alter the TH1/TH2 balance, thereby reshaping the tumor microenvironment and interfere with CLDN18.2-targeted therapies. Strategies including combining anti-PD1 antibody or CAF inhibitor, CLDN18.2-CAR-T plus CLDN18.2-antibody, and depleting plasma EVs, can sensitize CLDN18.2-CAR-T/antibody by countermeasuring EV-proteins’ therapeutic interferences. Collectively, our work provides potential options to monitor and improve CLDN18.2-targeted therapies in clinical practice. CLDN18.2-targeted CART and antibody therapies are promising for gastrointestinal cancers, but predictive biomarkers and strategies to enhance efficacy are needed. Here, these authors investigate how extracellular vesicle (EV)- derived proteins influence therapeutic response to CLDN18.2-based CAR-T and targeted therapies.
Preclinical proof-of-concept for a rationally designed CAR4-NK therapy against CLDN18.2-positive gastric cancer, in which CD28H-2B4 co-stimulatory domains enhance the effector function of CAR4-NK cells, and show the potential of irradiated CAR4-NK cells as a safer, controllable "off-the-shelf" product candidate.
Claudin 18.2 (CLDN18.2), a tight junction protein largely confined to normal gastric mucosa, is overexpressed and mislocalized on the surface of gastric, gastroesophageal, pancreatic, and other gastrointestinal cancers. This pattern has made CLDN18.2 a leading target in solid tumor immunotherapy. This review traces its...
Mohammad Bahrami, M. H. Makoui, Amir Bayat Bodaghi et al.· Biomarkers· 0 citations
Abstract Background Claudin 18.2 (CLDN18.2) is a promising therapeutic target for gastric, pancreatic and ovarian cancers. The Food and Drug Administration-approved antibody, zolbetuximab (IgG1), induces tumor cell death via antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis...
Lei Pei, Wan-Rong Zhang, Hao-Ran Zhu et al.· Journal for ImmunoTherapy of...· 0 citations
Background: Chimeric antigen receptor (CAR) T-cell therapy for solid tumors is limited by inadequate T-cell persistence and tumor infiltration, as well as treatment-associated cytokine release syndrome (CRS). To address these challenges, we developed a metabolically rewired CAR T-cell (MRCAR) platform by co-expressing...
Yue Hu, Kevin Song, Ruo-Ning Wang et al.· Biomedicines· 0 citations
Abstract Only a subset of patients with non–small cell lung cancer (NSCLC) benefits from immune checkpoint inhibitors (ICIs). Tissue PD-L1 has limited accuracy in predicting ICI response and requires invasive biopsies, highlighting the urgent need for reliable, minimally invasive biomarkers. Extracellular vesicle (EV)...
Chang-Chieh Hsu, Man Qi, Fumito Ito et al.· Cancer Research Communicatio...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.